Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) investors of a class action representing investors that bought securities between May 17, 2022, and July 19, 2024, inclusive (the “Class Period”). Allarity investors have until November 12, 2024 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The Complaint asserts that, throughout the Class Period, the Defendants issued materially false and misleading statements concerning the Company’s business practices, operations, and adherence to compliance policies. Specifically, it contends that the Defendants inflated the ongoing regulatory prospects of the Dovitinib NDA and engaged in illegal, illicit, or otherwise improper conduct related to the Dovitinib NDA and/or the Dovitinib-DRP PMA, involving Allarity and three of its former officers. This misconduct exposed the Company to heightened risks of regulatory and governmental scrutiny, enforcement actions, and significant legal, financial, and reputational damages. Following the disclosure that Allarity was under investigation for wrongdoing related to the Dovitinib NDA and/or Dovitinib-DRP PMA, the Company downplayed the likelihood of an enforcement action resulting from the investigation. As a result, the Company’s public statements were materially false and misleading throughout the relevant period.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com
Attorney Advertising
- ROSEN, A LEADING LAW FIRM, Encourages Stellantis N.V. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – STLA - October 6, 2024
- MRNA DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA - October 6, 2024
- NNE DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NANO Nuclear Energy, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 8 Deadline in Securities Class Action – NNE - October 6, 2024